Cardiology Search
Cardiology Cardiology
tachycardia
TACHYCARDIA

Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.

Divided into supraventricular and ventricular tachycardia.

Signs and symptoms related to rapid heart rate are altered sensorium, angina, shortness of breath, myocardial infarction, hypotension and other signs of shock (eg cold clammy skin, low urine output), heart failure or pulmonary congestion.

Drug Information

Indication: DVT & pulmonary embolism (PE). Prevention of stroke & systemic embolism in adult patients w/ non-valvu...

Indication: 75-mg & 110-mg cap: Primary prevention of venous thromboembolic events in adult patients who have undergon...

Indication: HTN.

Indication: Symptomatic supraventricular tachyarrhythmias requiring treatment eg, AV junctional or supraventricular tachyc...

Dosage: HTN 50-100 mg daily as a single dose. Arrhythmia Oral maintenance: 50-100 mg/day as a single dose. Angina 50 m

Dosage: HTN, angina pectoris & cardiac arrhythmias 100-200 mg as a single or divided dose. Increased as necessary.

Indication: Essential HTN, angina pectoris. Symptomatic, stable, chronic heart failure.

Indication: Adult patients suffering from MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or es...

Indication: Prevention of atherothrombotic events in MI (from a few days until <35 days), ischaemic stroke (7 days unti...

Indication: Prevention of artherothrombotic events eg, recent MI, stroke, established peripheral arterial disease; acute c...

1  /  7
1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Age, sex do not affect outcomes after PCI, CABG
2 days ago
Age and sex do not appear to influence outcomes after percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) for left main coronary artery disease, reports a recent study.
Untreated white coat hypertension ups risk of cardiovascular events, all-cause mortality
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
Heart failure patients with, without CKD fare well with individualized therapies
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.
ACC/AHA vs ESC/ESH guideline: Assessing impact on hypertension prevalence, treatment
23 Jun 2019
Implementing the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline over that of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) will give rise to a substantial increase in the prevalence of hypertension, as well as the number of adults who should receive medication, according to a study.